Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 0.80 |
| ▸ | GSK3B | P49841 | 1/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.69 |
| ▸ | IGF1R | P08069 | 4/20 | 0.69 |
| ▸ | INSR | P06213 | 3/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.69 |
| ▸ | BRAF | P15056 | 1/20 | 0.65 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146470 | 1.00 | MEN1 (1.00) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL13389108 | 0.81 | PIK3CG (0.74) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL14277836 | 0.81 | GSK3A (0.79) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL4200323 | 0.81 | PIK3CG (1.00) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL1064039 | 0.81 | PIK3CG (1.00) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL1064036 | 0.81 | PIK3CG (1.00) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL5147352 | 0.81 | MEN1 (0.67) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL5147357 | 0.81 | MEN1 (0.67) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL5144855 | 0.81 | IGF1R (0.74) | MEN1CASP3BLMKMT2ASENP8 | |
| SCHEMBL1063265 | 0.81 | MEN1 (0.67) | MEN1CASP3BLMKMT2ASENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | MEN1 4004/4885CASP3 1644/4885BLM 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.